|
CA1172255A
(en)
*
|
1980-12-11 |
1984-08-07 |
Robert R. Covington |
Buspirone process
|
|
JPH0635450B2
(en)
*
|
1984-03-16 |
1994-05-11 |
三井東圧化学株式会社 |
Thiocyanopyrimidine derivative, its production method and agricultural / horticultural fungicide
|
|
US5098902A
(en)
*
|
1991-03-18 |
1992-03-24 |
Warner-Lambert Company |
Method of treating neurodegenerative diseases
|
|
US5075305A
(en)
*
|
1991-03-18 |
1991-12-24 |
Warner-Lambert Company |
Compound, composition and use
|
|
ES2146614T3
(en)
*
|
1992-09-18 |
2000-08-16 |
Asahi Chemical Ind |
DERIVATIVES OF AZEPINA, PRODUCTION OF THE SAME AND ITS USE AS LIGANDS OF THE SIGMA RECEIVER.
|
|
US5658923A
(en)
*
|
1992-09-18 |
1997-08-19 |
Asahi Kasei Kogyo Kabushiki Kaisha |
Azepine derivatives and use thereof
|
|
CA2208900C
(en)
*
|
1996-07-18 |
2006-08-01 |
Lonza Ag |
Process for preparing 2-pyrimidinecarboxylates
|
|
CA2321153A1
(en)
|
1998-02-17 |
1999-08-19 |
Timothy D. Cushing |
Anti-viral pyrimidine derivatives
|
|
US6410726B1
(en)
|
2000-01-12 |
2002-06-25 |
Tularik Inc. |
Arylsulfonic acid salts of pyrimidine-based antiviral
|
|
AU2003295776B2
(en)
*
|
2002-11-21 |
2011-05-12 |
Novartis Vaccines And Diagnostics, Inc. |
2,4,6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer
|
|
EP1599468B1
(en)
*
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
SI1599468T1
(en)
*
|
2003-01-14 |
2008-02-29 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
|
PE20051029A1
(en)
|
2003-07-02 |
2005-12-07 |
Vertex Pharma |
VOLTAGE REGULATED ION CHANNEL MODULATING PYRIMIDINES
|
|
AR045047A1
(en)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
ARILO AND HETEROARILO DERIVATIVES TRISUSTITUIDOS AS MODULATORS OF METABOLISM AND PROFILAXIS AND TREATMENT OF DISORDERS RELATED TO THEMSELVES
|
|
CA2533901A1
(en)
|
2003-07-30 |
2005-02-10 |
Xenon Pharmaceuticals Inc. |
Piperazine derivatives and their use as therapeutic agents
|
|
NZ545265A
(en)
|
2003-07-30 |
2009-11-27 |
Xenon Pharmaceuticals Inc |
Pyridazine derivatives and their use for treating diseases mediated by stearoyl-CoA desaturase (SCD) enzymes
|
|
HUP0400405A3
(en)
*
|
2004-02-10 |
2009-03-30 |
Sanofi Synthelabo |
Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
|
|
JP2007217282A
(en)
*
|
2004-03-04 |
2007-08-30 |
Astellas Pharma Inc |
Substituted pyrimidine derivative
|
|
CA2580845A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
|
AR051202A1
(en)
|
2004-09-20 |
2006-12-27 |
Xenon Pharmaceuticals Inc |
HETEROCICLIC DERIVATIVES AND THEIR USE AS INHIBITORS OF ESTEAROIL-COA DESATURASA
|
|
WO2006034315A2
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
AU2005329423A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
CN101083994A
(en)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
Heterocyclic derivatives and their use as therapeutic agents
|
|
MX2007003321A
(en)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Heterocyclic derivatives and their use as therapeutic agents.
|
|
US7951805B2
(en)
|
2004-09-20 |
2011-05-31 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
|
DOP2006000010A
(en)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
PROCEDURE TO PREPARE AROMATIC ETERES
|
|
WO2006130493A2
(en)
|
2005-05-31 |
2006-12-07 |
Vertex Pharmaceuticals Incorporated |
Heterocycles useful as modulators of ion channels
|
|
BRPI0611187A2
(en)
|
2005-06-03 |
2010-08-24 |
Xenon Pharmaceuticals Inc |
amino thiazide derivatives as inhibitors of human stearoyl coa desaturase
|
|
GB0512844D0
(en)
*
|
2005-06-23 |
2005-08-03 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
PI-3 Kinase inhibitors and methods of their use
|
|
CA2675558A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
|
EP2197873B1
(en)
|
2007-09-20 |
2014-07-16 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
|
AU2009232721B2
(en)
*
|
2008-03-31 |
2013-02-14 |
Zenyaku Kogyo Kabushikikaisha |
Pyrimidine derivative having cell protecting effect and uses thereof
|
|
KR101787309B1
(en)
*
|
2008-12-09 |
2017-10-18 |
길리애드 사이언시즈, 인코포레이티드 |
Modulators of toll-like receptors
|
|
AU2011305525B2
(en)
|
2010-09-22 |
2016-08-18 |
Arena Pharmaceuticals, Inc. |
Modulators of the GPR119 receptor and the treatment of disorders related thereto
|
|
PE20141581A1
(en)
|
2011-09-27 |
2014-11-14 |
Novartis Ag |
3-PIRMIDIN-4-IL-OXAZOLIDIN-2-ONAS AS INHIBITORS OF MUTANT HDI
|
|
CN103204816B
(en)
|
2012-01-16 |
2016-04-27 |
中国人民解放军军事医学科学院毒物药物研究所 |
Piperazinylpyrimidine analog derivative and its production and use
|
|
UY34632A
(en)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
ES2665619T3
(en)
|
2013-03-14 |
2018-04-26 |
Novartis Ag |
3-Pyrimidin-4-yl-oxazolidin-2-ones as mutant HDI inhibitors
|
|
CN116850181A
(en)
|
2015-01-06 |
2023-10-10 |
艾尼纳制药公司 |
Treatment and S1P 1 Methods of receptor-related disorders
|
|
ES2929526T3
(en)
|
2015-06-22 |
2022-11-29 |
Arena Pharm Inc |
(R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl) acid L-arginine crystal salt acetic acid for use in disorders associated with the S1P1 receptor
|
|
MA47504A
(en)
|
2017-02-16 |
2019-12-25 |
Arena Pharm Inc |
COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS
|